Published in Cancer Gene Ther on December 01, 2005
Designer gene delivery vectors: molecular engineering and evolution of adeno-associated viral vectors for enhanced gene transfer. Pharm Res (2007) 1.50
Genetic control of wayward pluripotent stem cells and their progeny after transplantation. Cell Stem Cell (2009) 1.26
Targeting multiple pathways in gliomas with stem cell and viral delivered S-TRAIL and Temozolomide. Mol Cancer Ther (2008) 1.16
Combination therapy utilizing shRNA knockdown and an optimized resistant transgene for rescue of diseases caused by misfolded proteins. Proc Natl Acad Sci U S A (2011) 1.14
Intra-articular gene delivery and expression of interleukin-1Ra mediated by self-complementary adeno-associated virus. J Gene Med (2009) 0.95
AAV-mediated local delivery of interferon-beta for the treatment of retinoblastoma in preclinical models. Neuromolecular Med (2009) 0.95
The status of gene therapy for brain tumors. Expert Opin Biol Ther (2007) 0.95
Impact of VP1-specific protein sequence motifs on adeno-associated virus type 2 intracellular trafficking and nuclear entry. J Virol (2012) 0.94
Inhibition of angiogenesis and HCT-116 xenograft tumor growth in mice by kallistatin. World J Gastroenterol (2007) 0.93
Role of protein tyrosine phosphatases in cancer. Prog Nucleic Acid Res Mol Biol (2006) 0.92
Adeno-associated virus-mediated gene transfer. J Cell Biochem (2008) 0.91
A small regulatory element from chromosome 19 enhances liver-specific gene expression. Gene Ther (2008) 0.87
Transcriptional targeting of gene expression in breast cancer by the promoters of protein regulator of cytokinesis 1 and ribonuclease reductase 2. Exp Mol Med (2008) 0.85
Novel cytotoxic vectors based on adeno-associated virus. Toxins (Basel) (2010) 0.85
Antitumor effect of sFlt-1 gene therapy system mediated by Bifidobacterium Infantis on Lewis lung cancer in mice. Cancer Gene Ther (2011) 0.83
AAV-mediated human PEDF inhibits tumor growth and metastasis in murine colorectal peritoneal carcinomatosis model. BMC Cancer (2012) 0.82
Gene expression and gene therapy imaging. Eur Radiol (2006) 0.81
Adeno-associated virus (AAV) vectors in cancer gene therapy. J Control Release (2016) 0.80
Chemotherapeutic agents enhance AAV2-mediated gene transfer into breast cancer cells promoting CD40 ligand-based immunotherapy. J Cancer Res Clin Oncol (2006) 0.77
AAV2-mediated in vivo immune gene therapy of solid tumours. Genet Vaccines Ther (2010) 0.77
Adeno-associated viral vectors engineered for macrolide-adjustable transgene expression in mammalian cells and mice. BMC Biotechnol (2007) 0.76
Recombinant influenza viruses as delivery vectors for hepatis B virus epitopes. Clin Exp Vaccine Res (2012) 0.76
Acquisition of selective antitumoral effects of recombinant adeno-associated virus by genetically inserting tumor-targeting peptides into capsid proteins. Oncol Lett (2011) 0.76
Selective killing of Smad4-negative tumor cells via a designed repressor strategy. Mol Pharmacol (2008) 0.75
Enhanced transduction of colonic cell lines in vitro and the inflamed colon in mice by viral vectors, derived from adeno-associated virus serotype 2, using virus-microbead conjugates bearing lectin. BMC Biotechnol (2007) 0.75
Human β-NGF gene transferred to cat corneal endothelial cells. Int J Ophthalmol (2016) 0.75
Novel adeno-associated viruses from rhesus monkeys as vectors for human gene therapy. Proc Natl Acad Sci U S A (2002) 11.11
Membrane-associated heparan sulfate proteoglycan is a receptor for adeno-associated virus type 2 virions. J Virol (1998) 8.45
Gene therapy restores vision in a canine model of childhood blindness. Nat Genet (2001) 7.88
Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance. Nature (1997) 7.66
Induction of angiogenesis during the transition from hyperplasia to neoplasia. Nature (1989) 7.30
Clades of Adeno-associated viruses are widely disseminated in human tissues. J Virol (2004) 7.12
Second-strand synthesis is a rate-limiting step for efficient transduction by recombinant adeno-associated virus vectors. J Virol (1996) 6.22
Use of adeno-associated virus as a general transduction vector for mammalian cells. Curr Top Microbiol Immunol (1992) 6.16
Transduction with recombinant adeno-associated virus for gene therapy is limited by leading-strand synthesis. J Virol (1996) 5.94
Cross-packaging of a single adeno-associated virus (AAV) type 2 vector genome into multiple AAV serotypes enables transduction with broad specificity. J Virol (2002) 5.82
Evidence for gene transfer and expression of factor IX in haemophilia B patients treated with an AAV vector. Nat Genet (2000) 5.80
Human fibroblast growth factor receptor 1 is a co-receptor for infection by adeno-associated virus 2. Nat Med (1999) 5.50
AlphaVbeta5 integrin: a co-receptor for adeno-associated virus type 2 infection. Nat Med (1999) 5.26
Adeno-associated virus terminal repeat (TR) mutant generates self-complementary vectors to overcome the rate-limiting step to transduction in vivo. Gene Ther (2003) 4.92
Effects of angiogenesis inhibitors on multistage carcinogenesis in mice. Science (1999) 4.91
Persistent and therapeutic concentrations of human factor IX in mice after hepatic gene transfer of recombinant AAV vectors. Nat Genet (1997) 4.72
Infectious clones and vectors derived from adeno-associated virus (AAV) serotypes other than AAV type 2. J Virol (1998) 4.71
Gene therapy vectors based on adeno-associated virus type 1. J Virol (1999) 4.63
Real-time single-molecule imaging of the infection pathway of an adeno-associated virus. Science (2001) 4.61
AAV-mediated factor IX gene transfer to skeletal muscle in patients with severe hemophilia B. Blood (2002) 4.60
Recombinant adeno-associated virus type 2, 4, and 5 vectors: transduction of variant cell types and regions in the mammalian central nervous system. Proc Natl Acad Sci U S A (2000) 4.39
Characterization of a preferred site on human chromosome 19q for integration of adeno-associated virus DNA by non-homologous recombination. EMBO J (1992) 4.36
Self-complementary recombinant adeno-associated virus (scAAV) vectors promote efficient transduction independently of DNA synthesis. Gene Ther (2001) 4.35
The atomic structure of adeno-associated virus (AAV-2), a vector for human gene therapy. Proc Natl Acad Sci U S A (2002) 4.30
The three-dimensional structure of canine parvovirus and its functional implications. Science (1991) 3.87
Infectious entry pathway of adeno-associated virus and adeno-associated virus vectors. J Virol (2000) 3.84
Stable gene transfer and expression of human blood coagulation factor IX after intramuscular injection of recombinant adeno-associated virus. Proc Natl Acad Sci U S A (1997) 3.84
Cloning and characterization of adeno-associated virus type 5. J Virol (1999) 3.36
Several log increase in therapeutic transgene delivery by distinct adeno-associated viral serotype vectors. Mol Ther (2000) 3.32
Mutational analysis of the adeno-associated virus type 2 (AAV2) capsid gene and construction of AAV2 vectors with altered tropism. J Virol (2000) 3.27
Quantitative analysis of the packaging capacity of recombinant adeno-associated virus. Hum Gene Ther (1996) 3.26
Identification of a heparin-binding motif on adeno-associated virus type 2 capsids. J Virol (2003) 3.25
Transduction of dendritic cells by DNA viral vectors directs the immune response to transgene products in muscle fibers. J Virol (1998) 3.14
Adeno-associated virus serotype 4 (AAV4) and AAV5 both require sialic acid binding for hemagglutination and efficient transduction but differ in sialic acid linkage specificity. J Virol (2001) 3.11
Random peptide libraries displayed on adeno-associated virus to select for targeted gene therapy vectors. Nat Biotechnol (2003) 3.01
Adeno-associated virus type 5 (AAV5) but not AAV2 binds to the apical surfaces of airway epithelia and facilitates gene transfer. J Virol (2000) 3.00
Restoration of photoreceptor ultrastructure and function in retinal degeneration slow mice by gene therapy. Nat Genet (2000) 3.00
Adeno-associated virus type 6 (AAV6) vectors mediate efficient transduction of airway epithelial cells in mouse lungs compared to that of AAV2 vectors. J Virol (2001) 2.95
Identification of amino acid residues in the capsid proteins of adeno-associated virus type 2 that contribute to heparan sulfate proteoglycan binding. J Virol (2003) 2.93
Cloning of adeno-associated virus type 4 (AAV4) and generation of recombinant AAV4 particles. J Virol (1997) 2.91
Preclinical in vivo evaluation of pseudotyped adeno-associated virus vectors for liver gene therapy. Blood (2003) 2.74
Attenuation of seizures and neuronal death by adeno-associated virus vector galanin expression and secretion. Nat Med (2003) 2.70
Increasing the size of rAAV-mediated expression cassettes in vivo by intermolecular joining of two complementary vectors. Nat Biotechnol (2000) 2.58
Intracellular trafficking of adeno-associated virus vectors: routing to the late endosomal compartment and proteasome degradation. J Virol (2001) 2.56
Characterization of the DNA of a defective human parvovirus isolated from a genital site. Virology (1984) 2.49
The VP1 capsid protein of adeno-associated virus type 2 is carrying a phospholipase A2 domain required for virus infectivity. J Gen Virol (2002) 2.44
Identification of PDGFR as a receptor for AAV-5 transduction. Nat Med (2003) 2.43
Chronic suppression of heart-failure progression by a pseudophosphorylated mutant of phospholamban via in vivo cardiac rAAV gene delivery. Nat Med (2002) 2.37
Adeno-associated viruses. Adv Virus Res (1979) 2.35
Subcellular compartmentalization of adeno-associated virus type 2 assembly. J Virol (1997) 2.31
Nucleotide sequencing and generation of an infectious clone of adeno-associated virus 3. Virology (1996) 2.26
Genetic capsid modifications allow efficient re-targeting of adeno-associated virus type 2. Nat Med (1999) 2.24
Microdystrophin gene therapy of cardiomyopathy restores dystrophin-glycoprotein complex and improves sarcolemma integrity in the mdx mouse heart. Circulation (2003) 2.22
Persistent expression of human clotting factor IX from mouse liver after intravenous injection of adeno-associated virus vectors. Proc Natl Acad Sci U S A (1997) 2.22
Functional implications of the structure of the murine parvovirus, minute virus of mice. Structure (1998) 2.17
Sustained expression of therapeutic level of factor IX in hemophilia B dogs by AAV-mediated gene therapy in liver. Mol Ther (2000) 2.12
Endocytosis and nuclear trafficking of adeno-associated virus type 2 are controlled by rac1 and phosphatidylinositol-3 kinase activation. J Virol (2000) 2.08
Structure, sequence, and function correlations among parvoviruses. Virology (1993) 2.06
Selective and rapid uptake of adeno-associated virus type 2 in brain. Hum Gene Ther (1998) 2.06
Adeno-associated virus Rep proteins target DNA sequences to a unique locus in the human genome. J Virol (1997) 2.06
Impaired intracellular trafficking of adeno-associated virus type 2 vectors limits efficient transduction of murine fibroblasts. J Virol (2000) 2.01
Molecular cloning of adeno-associated virus variant genomes and generation of infectious virus by recombination in mammalian cells. J Biol Chem (1984) 1.99
Structure determination of feline panleukopenia virus empty particles. Proteins (1993) 1.99
Dynamin is required for recombinant adeno-associated virus type 2 infection. J Virol (1999) 1.99
Epitope mapping of human anti-adeno-associated virus type 2 neutralizing antibodies: implications for gene therapy and virus structure. J Virol (2000) 1.98
Adeno-associated viral vector-mediated gene transfer of human blood coagulation factor IX into mouse liver. Blood (1998) 1.96
Trans-splicing vectors expand the utility of adeno-associated virus for gene therapy. Proc Natl Acad Sci U S A (2000) 1.95
Nigrostriatal alpha-synucleinopathy induced by viral vector-mediated overexpression of human alpha-synuclein: a new primate model of Parkinson's disease. Proc Natl Acad Sci U S A (2003) 1.92
Sustained correction of bleeding disorder in hemophilia B mice by gene therapy. Proc Natl Acad Sci U S A (1999) 1.90
Recruitment of wild-type and recombinant adeno-associated virus into adenovirus replication centers. J Virol (1996) 1.86
Concatamerization of adeno-associated virus circular genomes occurs through intermolecular recombination. J Virol (1999) 1.84
Gene therapy with brain-derived neurotrophic factor as a protection: retinal ganglion cells in a rat glaucoma model. Invest Ophthalmol Vis Sci (2003) 1.83
A phase I study of an adeno-associated virus-CFTR gene vector in adult CF patients with mild lung disease. Hum Gene Ther (1996) 1.80
Adeno-associated virus vector gene expression occurs in nondividing cells in the absence of vector DNA integration. Am J Respir Cell Mol Biol (1994) 1.80
Overcoming adeno-associated virus vector size limitation through viral DNA heterodimerization. Nat Med (2000) 1.79
Incorporation of tumor-targeting peptides into recombinant adeno-associated virus capsids. Mol Ther (2001) 1.78
Expanding AAV packaging capacity with trans-splicing or overlapping vectors: a quantitative comparison. Mol Ther (2001) 1.78
Insertional mutagenesis of AAV2 capsid and the production of recombinant virus. Virology (1999) 1.76
Adeno-associated virus (AAV)-3-based vectors transduce haematopoietic cells not susceptible to transduction with AAV-2-based vectors. J Gen Virol (2000) 1.73
Gene therapy strategy for long-term myocardial protection using adeno-associated virus-mediated delivery of heme oxygenase gene. Circulation (2002) 1.67
Sustained and complete phenotype correction of hemophilia B mice following intramuscular injection of AAV1 serotype vectors. Mol Ther (2001) 1.65
Cross-dressing the virion: the transcapsidation of adeno-associated virus serotypes functionally defines subgroups. J Virol (2004) 1.64
Clinical protocol. Gene therapy of Canavan disease: AAV-2 vector for neurosurgical delivery of aspartoacylase gene (ASPA) to the human brain. Hum Gene Ther (2002) 1.60
How do animal DNA viruses get to the nucleus? Annu Rev Microbiol (1998) 1.59
Regulated delivery of therapeutic proteins after in vivo somatic cell gene transfer. Science (1999) 1.57
Structural analysis of adeno-associated virus transduction circular intermediates. Virology (1999) 1.56
Design and packaging of adeno-associated virus gene targeting vectors. J Virol (2000) 1.54
Generation and characterization of chimeric recombinant AAV vectors. Mol Ther (2003) 1.54
In vitro selection of viral vectors with modified tropism: the adeno-associated virus display. Mol Ther (2003) 1.53
Direct intramuscular injection with recombinant AAV vectors results in sustained expression in a dog model of hemophilia. Gene Ther (1998) 1.52
Targeted adeno-associated virus vector transduction of nonpermissive cells mediated by a bispecific F(ab'gamma)2 antibody. Nat Biotechnol (1999) 1.51
Glial cell line derived neurotrophic factor delays photoreceptor degeneration in a transgenic rat model of retinitis pigmentosa. Mol Ther (2001) 1.47
Adeno-associated virus vectors for gene therapy: more pros than cons? Mol Med Today (2000) 1.45
CD40 ligand-dependent activation of cytotoxic T lymphocytes by adeno-associated virus vectors in vivo: role of immature dendritic cells. J Virol (2000) 1.39
The structure of human parvovirus B19 at 8 A resolution. Virology (1994) 1.38
Insertional mutagenesis of the adeno-associated virus type 2 (AAV2) capsid gene and generation of AAV2 vectors targeted to alternative cell-surface receptors. Hum Gene Ther (2001) 1.35
Synergy between angiostatin and endostatin: inhibition of ovarian cancer growth. Cancer Res (2000) 1.34
Recombinant AAV-mediated expression of galanin in rat hippocampus suppresses seizure development. Eur J Neurosci (2003) 1.32
Alpha2,3 and alpha2,6 N-linked sialic acids facilitate efficient binding and transduction by adeno-associated virus types 1 and 6. J Virol (2006) 2.79
Polymeric nanogels produced via inverse microemulsion polymerization as potential gene and antisense delivery agents. J Am Chem Soc (2002) 1.98
Cross-dressing the virion: the transcapsidation of adeno-associated virus serotypes functionally defines subgroups. J Virol (2004) 1.64
Role of viral vectors and virion shells in cellular gene expression. Mol Ther (2004) 1.40
Oxygen-coupled redox regulation of the skeletal muscle ryanodine receptor-Ca2+ release channel by NADPH oxidase 4. Proc Natl Acad Sci U S A (2011) 1.19
Existence of transient functional double-stranded DNA intermediates during recombinant AAV transduction. Proc Natl Acad Sci U S A (2007) 1.12
Single-polarity recombinant adeno-associated virus 2 vector-mediated transgene expression in vitro and in vivo: mechanism of transduction. Mol Ther (2007) 1.10
Single amino acid modification of adeno-associated virus capsid changes transduction and humoral immune profiles. J Virol (2012) 1.04
Oversized AAV transductifon is mediated via a DNA-PKcs-independent, Rad51C-dependent repair pathway. Mol Ther (2013) 1.02
Production of recombinant adeno-associated viral vectors and use in in vitro and in vivo administration. Curr Protoc Neurosci (2011) 0.97
Production of recombinant adeno-associated viral vectors for in vitro and in vivo use. Curr Protoc Mol Biol (2007) 0.97
Retracted Osteopontin and protein kinase C regulate PDLIM2 activation and STAT1 ubiquitination in LPS-treated murine macrophages. J Biol Chem (2010) 0.88
p53 must be competent for transcriptional regulation to suppress tumor formation. Oncogene (2005) 0.87
Adaptation in a mouse colony monoassociated with Escherichia coli K-12 for more than 1,000 days. Appl Environ Microbiol (2010) 0.87
Proteomic analysis of the NOS2 interactome in human airway epithelial cells. Nitric Oxide (2013) 0.83
Production of recombinant adeno-associated viral vectors. Curr Protoc Hum Genet (2007) 0.83
Production of recombinant adeno-associated viral vectors and use for in vitro and in vivo administration. Curr Protoc Neurosci (2006) 0.82
Adeno-associated Virus as a Mammalian DNA Vector. Microbiol Spectr (2015) 0.82
Adeno-associated viral vectors based on serotype 3b use components of the fibroblast growth factor receptor signaling complex for efficient transduction. Hum Gene Ther (2012) 0.81
AMPK and substrate availability regulate creatine transport in cultured cardiomyocytes. Am J Physiol Endocrinol Metab (2011) 0.80
Preclinical toxicity evaluation of AAV for pain: evidence from human AAV studies and from the pharmacology of analgesic drugs. Mol Pain (2014) 0.80
X-linked inhibitor of apoptosis protein-mediated attenuation of apoptosis, using a novel cardiac-enhanced adeno-associated viral vector. Hum Gene Ther (2012) 0.79
Reproducibility of left atrial ablation with high-intensity focused ultrasound energy in a calf model. J Thorac Cardiovasc Surg (2010) 0.79
Gene therapy for the prevention of vein graft disease. Transl Res (2012) 0.78
Targeted integration by adeno-associated virus. Methods Mol Med (2003) 0.76
Short-lived alpha-helical intermediates in the folding of beta-sheet proteins. Biochemistry (2010) 0.76
Utility of telomerase-pot1 fusion protein in vascular tissue engineering. Cell Transplant (2009) 0.75
Plasma levels of microRNA-155 are upregulated with long-term left ventricular assist device support. ASAIO J (2017) 0.75
Osteopontin and protein kinase C regulate PDLIM2 activation and STAT1 ubiquitination in LPS-treated murine macrophages. J Biol Chem (2017) 0.75